ATEX is navigating a bruising month — down 15% — while a cluster of executives quietly sold shares near the highs, and a confirmed activist remains on the register with a 28.5% stake.
The insider selling is the clearest signal from this week's data. Four separate executives filed open-market sales between September 8 and September 10, none under a 10b5-1 pre-arranged plan. The Chief Marketing Officer sold 8,064 shares at around $84.20, raising just under $679,000. The Chief Legal Officer sold more than 4,300 shares across two transactions at $85.44. A director followed with two tranches — 1,200 shares on September 4 and 2,500 on September 10. In aggregate, net insider selling over the past 90 days amounts to roughly 284,000 shares worth $24.3 million. That is a meaningful number on a stock with a float of around 19 million shares, and none of these trades carry the exemption of a pre-announced selling plan.
The activist backdrop gives that selling added complexity. Jeffrey A. Altman filed a Schedule 13D/A in July disclosing a 28.5% stake — an activist-intent filing, not a passive one. Heard Capital LLC holds a further 9.4% under its own 13D/A filing. Together, these two holders control more than a third of the company on last-disclosed figures. T. Rowe Price holds another 15.8% on its most recent report. The shareholder base is extraordinarily concentrated. As always with 13D/G disclosures, stakes reflect positions as last reported around the 5% threshold; a holder can reduce below 5% without filing again. But with Altman and Heard both filing activist-intent forms, the strategic pressure on management is real and disclosed.
Short interest adds a separate layer of tension. Bears hold 8.9% of the free float — a meaningful but not extreme position — and that number has been falling sharply this week, down nearly 15% over seven days. The drop suggests some covering into the price weakness. Borrow remains essentially free at roughly 0.5%, and availability is running near 200%, meaning there is plenty of capacity for new shorts if sentiment sours further. The ORTEX short score has been range-bound in the low-to-mid 60s all week — elevated but not flashing a squeeze or capitulation signal.
Options positioning has grown more defensive as the stock has retreated. The put/call ratio climbed to 0.22, running above its 20-day average of 0.17 by more than one standard deviation. That is still a modest level in absolute terms — well below the 52-week high of 0.77 — but the direction of travel is clear: options traders have been adding more downside protection as the stock fell. The move tracks the price decline closely, with the PCR rising steadily from sub-0.14 levels in late August.
On the Street, analyst coverage is thin and the most recent action is stale by more than 30 days. JP Morgan lowered its target modestly to $130 in mid-August while keeping an Overweight rating — implying nearly 70% upside from the current $76.99 close. B. Riley downgraded to Neutral back in June with a $69 target, now marginally below where the stock is trading. The mean target across the two active ratings is $112, suggesting the Street still sees substantial value, but the recent earnings history is not encouraging: ATEX fell 4.3% and 7.5% on the days following the last two earnings prints, with further losses in the weeks after each.
The next earnings event is pencilled in for November 12. With insiders selling at prices above the current level, an activist sitting at 28.5%, short interest covering but still elevated, and the stock down 15% in a month, the setup into that print is one where the spread between the JP Morgan bull case and the B. Riley neutral case will be the central debate to watch.
See the live data behind this article on ORTEX.
Open ATEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
